217 related articles for article (PubMed ID: 25782201)
21. [Pharmacological and clinical profiles of long-lasting erythropoiesis-stimulating agent (darbepoetin alfa; NESP].
Nagano N
Nihon Yakurigaku Zasshi; 2008 Apr; 131(4):291-9. PubMed ID: 18408341
[No Abstract] [Full Text] [Related]
22. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.
Robles NR
Clin Drug Investig; 2016 Jun; 36(6):421-31. PubMed ID: 26894799
[TBL] [Abstract][Full Text] [Related]
23. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
24. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices.
Trkulja V
Med Hypotheses; 2012 Jan; 78(1):157-61. PubMed ID: 22078846
[TBL] [Abstract][Full Text] [Related]
25. Comparison of recombinant human erythropoietin and darbepoetin alpha in children.
Can C; Emre S; Bilge I; Yilmaz A; Şirin A
Pediatr Int; 2013 Jun; 55(3):296-9. PubMed ID: 23461764
[TBL] [Abstract][Full Text] [Related]
26. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
[TBL] [Abstract][Full Text] [Related]
27. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
Wish JB; Coyne DW
Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
[TBL] [Abstract][Full Text] [Related]
28. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
[TBL] [Abstract][Full Text] [Related]
29. Erythropoiesis-stimulating agents in kidney and cardiac disease.
Fluck R
Br J Hosp Med (Lond); 2006 Oct; 67(10):533-7. PubMed ID: 17069130
[No Abstract] [Full Text] [Related]
30. Use of Carnitor for Epogen resistant anemia.
Simard JC
ANNA J; 1999 Feb; 26(1):41-2. PubMed ID: 10222857
[TBL] [Abstract][Full Text] [Related]
31. Use of methoxy polyethylene glycol-epoetin beta in stage 3, 4 or 5 non-dialysis chronic kidney disease.
Padullés-Zamora N; Comas-Sugrañes D; Pineda-Yuste Mdel M; Jódar-Masanés R; Martínez-Castelao A
Nefrologia; 2012; 32(2):221-7. PubMed ID: 22421952
[TBL] [Abstract][Full Text] [Related]
32. Diabetes, anemia and CKD: Why TREAT?
Singh AK
Curr Diab Rep; 2010 Aug; 10(4):291-6. PubMed ID: 20544312
[TBL] [Abstract][Full Text] [Related]
33. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
Jones M; Ibels L; Schenkel B; Zagari M
Kidney Int; 2004 Mar; 65(3):757-67. PubMed ID: 14871396
[TBL] [Abstract][Full Text] [Related]
34. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
Hirai T; Nishizawa Y; Nakazono H; Asai M; Yamashita H; Sasaki A; Yamashita T; Yamashita K; Shigemoto K; Harada S; Mizuiri S
Ther Apher Dial; 2013 Oct; 17(5):498-503. PubMed ID: 24107278
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit.
To LL; Stoner CP; Stolley SN; Buenviaje JD; Ziegler TW
Am J Health Syst Pharm; 2001 Nov; 58(21):2061-5. PubMed ID: 11715828
[No Abstract] [Full Text] [Related]
36. Anemia management and chronic renal failure progression.
Rossert J; Froissart M; Jacquot C
Kidney Int Suppl; 2005 Dec; (99):S76-81. PubMed ID: 16336582
[TBL] [Abstract][Full Text] [Related]
37. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
[TBL] [Abstract][Full Text] [Related]
38. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
Voils SA; Harpe SH; Brophy GM
Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
[TBL] [Abstract][Full Text] [Related]
39. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.
Bieber E
J Reprod Med; 2001 May; 46(5 Suppl):521-30. PubMed ID: 11396386
[TBL] [Abstract][Full Text] [Related]
40. Managing anemia in patients with chronic kidney disease or cancer: development and role of darbepoetin alfa.
Scott SD
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):129S-132S. PubMed ID: 12222582
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
